ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
World Health Organization, 2005. Regional Strategic Framework for Elimination of Kala-azar from the South-East Asia Region (2005–2015). New Delhi: World Health Organization. Available at: http://www.searo.who.int/LinkFiles/Kala_azar_VBC-85_Rev_1.pdf. Accessed April 27, 2010.
-
2.
Singh SP, Reddy DC, Rai M, Sundar S, 2006. Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India. Trop Med Int Health 11: 899–905.
-
3.
Joshi A, Narain JP, Prasittisuk C, Bhatia R, Hashim G, Jorge A, Banjara M, Kroeger A, 2008. Can visceral leishmaniasis be eliminated from Asia? J Vector Borne Dis 45: 105–111.
-
4.
Thakur CP, Narayan S, Ranjan A, 2004. Epidemiological, clinical and pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Indian J Med Res 120: 166–172.
-
5.
Das VN, Ranjan A, Bimal S, Siddique NA, Pandey K, Kumar N, Verma N, Singh VP, Sinha PK, Bhattacharya SK, 2005. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar. Natl Med J India 18: 131–133.
-
6.
Croft SL, Sundar S, Fairlamb AH, 2006. Drug resistance in leishmaniasis. Clin Microbiol Rev 19: 111–126.
-
7.
Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK, 2007. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 356: 2571–2581.
-
8.
Deray G, 2002. Amphotericin B nephrotoxicity. J Antimicrob Chemother 49 (Suppl 1): 37–41.
-
9.
Meheus F, Boelaert M, Baltussen R, Sundar S, 2006. Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India. Trop Med Int Health 11: 1715–1724.
-
10.
Barratt G, Legrand P, 2005. Comparison of the efficacy and pharmacology of formulations of amphotericin B used in treatment of leishmaniasis. Curr Opin Infect Dis 18: 527–530.
-
11.
More B, Bhatt H, Kukreja V, Ainapure S, 2003. Miltefosine: great expectations against visceral leishmaniasis. J Postgrad Med 49: 101–103.
-
12.
Sundar S, Gupta LB, Makharia MK, Singh MK, Voss A, Rosenkaimer F, Engel J, Murray HW, 1999. Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 93: 589–597.
-
13.
Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fisher C, Voss A, Berman J, 1999. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 341: 1795–1800.
-
14.
Prasad R, Kumar R, Jaiswal BP, Singh UK, 2004. Miltefosine: an oral drug for visceral leishmaniasis. Indian J Pediatr 71: 143–144.
-
15.
Bhattacharya SK, Sur D, Sinha PK, Karbwang J, 2006. Elimination of leishmaniasis (kala-azar) from the Indian subcontinent is technically feasible and operationally achievable. Indian J Med Res 123: 195–196.
-
16.
Jha TK, Sundar S, Thakur CP, Felton JM, Sabin AJ, Horton J, 2005. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am J Trop Med Hyg 73: 1005–1011.
-
17.
Wasunna MK, Rashid JR, Mbui J, Kirigi G, Kinoti D, Lodenyo H, Felton JM, Sabin AJ, Albert MJ, Horton J, 2005. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am J Trop Med Hyg 73: 871–876.
-
18.
Dietze R, Carvalho SF, Valli LC, Berman J, Brewer T, Milhous W, Sanchez J, Schuster B, Grogl M, 2001. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 65: 685–689.
-
19.
Sherwood JA, Gachihi GS, Muigai RK, Skillman DR, Mugo M, Rashid JR, Wasunna KM, Were JB, Kasili SK, Mbugua JM, Kirigi G, Shaefer KU, Oster CN, Fleckenstein LL, Berman JD, Brewer TG, Roberts CR, Johnson AJ, Schuster BG, 1994. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin Infect Dis 19: 1034–1039.
-
20.
Yeates C, 2002. Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute). Curr Opin Investig Drugs 3: 1446–1452.
-
21.
National Cancer Institute, 2003. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD: National Cancer Institute. Available at: http://ctep.cancer.gov/reporting/ctc.html. Accessed April 27, 2010.
-
22.
National Institute of Allergy and Infectious Diseases (NIAID), US, Division of Microbiology and Infectious Diseases, 2001. Adult Toxicity Table.
-
23.
Chulay JD, Bryceson AD, 1983. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 32: 475–479.
-
24.
Steinijans VW, Diletti E, 1983. Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals. Eur J Clin Pharmacol 24: 127–136.
-
25.
Sundar S, Chakravarty J, Rai VK, Agrawal N, Singh SP, Chauhan V, Murray HW, 2007. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin Infect Dis 45: 556–561.
-
26.
Thakur CP, Narayan S, 2004. A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis. Ann Trop Med Parasitol 98: 129–138.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 0 | 0 | 0 |
| Full Text Views | 203 | 92 | 1 |
| PDF Downloads | 40 | 13 | 0 |
.png)
Pharmacokinetics of Oral Sitamaquine Taken with or without Food and Safety and Efficacy for Treatment of Visceral Leishmaniais: A Randomized Study in Bihar, India
This randomized, open-label study of patients in India with visceral leishmaniasis (VL) investigated the effect of food on sitamaquine and desethyl-sitamaquine pharmacokinetics. Patients were randomized to receive oral sitamaquine, 2 mg/kg/day, once a day for 21 days across four cohorts (n = 41) (fasted/fed, fed/fasted, fed/fed, and fasted/fasted) over two periods (days 1−10 and 11−21), or intravenous amphotericin B (AmB), 1 mg/kg every other day for 30 days (n = 20). Mean day 21 pharmacokinetics across the four cohorts were sitamaquine, area under curve (AUC)(0−τ) = 6,627−8,903 ng.hr/mL, AUC(0−16) = 4,859−6,633 ng.hr/mL, maximum plasma concentration (Cmax) = 401−570 ng/mL, apparent terminal half-life (t1/2) = 18.3−22.8 hr, time to reach Cmax (tmax) = 3.5−6 hr; and desethyl-sitamaquine, AUC(0−τ) = 2,307−3,163 ng.hr/mL, Cmax = 109−154 ng/mL, t1/2 = 23.0−27.9 hr, tmax = 2−10 hr, with no significant food effect. On-therapy adverse events were observed for sitamaquine in 4 (10%) of 41 patients and for AmB in 17 (85%) of 20 patients. The final clinical cure (day 180) was 85% (95% confidence interval = 70.8–94.4%) for sitamaquine and 95% (95% confidence interval = 75.1–99.9) for AmB. Sitamaquine can be taken regardless of food intake, was generally well tolerated, and showed potential efficacy in patients with visceral leishmaniasis.
Author Notes
Financial support: Sitamaquine development to date has been supported by GlaxoSmithKline PLC.
Disclosure: GlaxoSmithKline conducted the study and collected and analyzed data. All authors had access to the primary data and take responsibility for data reporting accuracy and completeness. The corresponding authors had responsibility for the final decision to submit for publication. Shyam Sundar has received support for clinical trials and travel funds to attend scientific meetings from Paladin Labs, Institute for One World Health, GlaxoSmithKline, Bharat Serum and Vaccine Ltd., Drugs for Neglected Diseases Initiative, National Institute of Allergy and Infectious Diseases, National Institutes of Health, World Health Organization, and the European Commission. Prabhat K. Sinha has received support from the Institute for One World Health, GlaxoSmithKline, Drugs for Neglected Diseases Initiative, World Health Organization, Médecins Sans Frontières (Barcelona) for clinical trials and travel funds to attend scientific meetings. Susan A. Dixon, Renata Buckley, Ann K. Miller, and Khadeeja Mohamed are employees of GlaxoSmithKline as noted in the affiliations. Mahir Al-Banna is a contractor employed by GlaxoSmithKline as noted in the affiliations.
Authors' addresses: Shyam Sundar, Kala-azar Medical Research Centre, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India, E-mail: drshyamsundar@hotmail.com. Prabhat K. Sinha, Rajendra Memorial Research Institute of Medical Sciences, Indian Council of Medical Research, Agamkuan Patna, Bihar 800 007, India, E-mail: pksinha18@yahoo.com. Susan A. Dixon, Infectious Diseases–Medicines Development Centre, Diseases of the Developing World, GlaxoSmithKline Research and Development, Stockley Park West, Uxbridge, Middlesex UB11 1BT, United Kingdom, E-mail: susan.x.dixon@gsk.com. Renata Buckley, Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline Research and Development, Stockley Park West, Uxbridge, Middlesex UB11 1BT, United Kingdom, E-mail: renata.2.buckley@gsk.com. Ann K. Miller, Clinical Pharmacology, Modelling and Simulation, Quantitative Sciences, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 19406, E-mail: ann.k.miller@gsk.com. Khadeeja Mohamed, Infectious Diseases–Medicines Development Centre, Biomedical Data Sciences, GlaxoSmithKline Research and Development, Stockley Park West, Uxbridge, Middlesex, United Kingdom, E-mail: khadeeja.m.mohamed@gsk.com. Mahir Al-Banna, Al-Banna Consulting, LLC, c/o GlaxoSmithKline Biostatistics and Programming Management, GlaxoSmithKline, 1250 South Collegeville Road, PO Box 5089, Collegeville, PA 19426-0989, E-mail: mahir.2.al-banna@gsk.com.